The Analytical Scientist / Issues / 2026 / February / Meeting the GLP1 Challenge with HighResolution Mass Spec
Pharma and Biopharma Pharma and Biopharma

Meeting the GLP-1 Challenge with High-Resolution Mass Spec

Veloxity Labs and SCIEX team up to advance peptide bioanalysis; here, the teams discuss how the GLP-1 boom is reshaping workflows and raising the bar for analytical performance

By James Strachan 02/25/2026 5 min read

Share

5 Key Takeaways

  • 1

    Peptide therapeutics, particularly GLP-1 receptor agonists, are driving demand for lower quantification limits and faster method development in bioanalytical labs.

  • 2

    Veloxity Labs has integrated high-resolution accurate-mass (HRAM) capabilities with the SCIEX ZenoTOF 8600 to enhance peptide analysis workflows.

  • 3

    The introduction of HRAM systems improves selectivity, sensitivity, and speed, addressing challenges posed by complex matrices and low sample volumes.

  • 4

    Both HRAM and triple-quadrupole mass spectrometers are essential in bioanalytical labs, providing complementary strengths for peptide analysis.

  • 5

    Emerging best practices include optimized sample preparation techniques and automated workflows to enhance throughput and reproducibility in peptide analysis.

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

Recommended

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment